Fig. 8: Correlation of PRMT1 expression with ME2 methylation and clinical prognosis of HCC.

A–C Immunohistochemical staining assay of the methylation levels of PRMT1 (A), ME2 (B), and ME2 expression in 73 paired human paracarcinomas, primary foci, and metastatic foci. D, K Images of immunohistochemical analysis of the expression levels of PRMT1, ME2, and ME2-R67K. E–G Correlation of PRMT1 (E), ME2 (F), ME2-R67K (G) in HCC tissues analyzed after immunohistochemical scoring. H–J. Cardinality analysis of expression correlation of PRMT1 (H), ME2 (I), ME2-R67K (J) after post immunohistochemical scoring. L, M Cardinality analysis of correlation between ME2-R67K expression and tumor size (L) and tumor pathological grade (M). N, O Survival analysis of association between ME2-R67K expression and prognosis of HCC patients.